Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Ford

Showing results (451-460 of 508) with videos related to

Pageof 51
Sort By:
Nature Genetics|October 10, 2018
Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome mapsAnubha Mahajan, Daniel Taliun, Matthias Thurner, et al.
Nature Communications|October 15, 2017
Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevityPeter K Joshi, Nicola Pirastu, Katherine A Kentistou, et al.
Lancet (London, England)|March 17, 2012
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis, Daniel I Swerdlow, Michael V Holmes, et al.
The New England Journal of Medicine|March 3, 2016
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease, Nathan O Stitziel, Kathleen E Stirrups, et al.
Journal of the American College of Cardiology|February 18, 2017
Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery DiseaseThomas R Webb, Jeanette Erdmann, Kathleen E Stirrups, et al.
Nature Communications|October 28, 2018
Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulationAlexander Teumer, Layal Chaker, Stefan Groeneweg, et al.
The Lancet. Diabetes & Endocrinology|December 3, 2016
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation studyAmand F Schmidt, Daniel I Swerdlow, Michael V Holmes, et al.
Lancet (London, England)|September 29, 2014
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trialsDaniel I Swerdlow, David Preiss, Karoline B Kuchenbaecker, et al.
Science Translational Medicine|June 3, 2016
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart diseaseRobert A Scott, Daniel F Freitag, Li Li, et al.
Nature Genetics|September 8, 2015
A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery diseaseMajid Nikpay, Anuj Goel, Hong-Hee Won, et al.
Pageof 51

Showing results (451-460 of 508) with videos related to

Sort By:
Pageof 51
Nature Genetics|October 10, 2018
Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome mapsAnubha Mahajan, Daniel Taliun, Matthias Thurner, et al.
Nature Communications|October 15, 2017
Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevityPeter K Joshi, Nicola Pirastu, Katherine A Kentistou, et al.
Lancet (London, England)|March 17, 2012
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis, Daniel I Swerdlow, Michael V Holmes, et al.
The New England Journal of Medicine|March 3, 2016
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease, Nathan O Stitziel, Kathleen E Stirrups, et al.
Journal of the American College of Cardiology|February 18, 2017
Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery DiseaseThomas R Webb, Jeanette Erdmann, Kathleen E Stirrups, et al.
Nature Communications|October 28, 2018
Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulationAlexander Teumer, Layal Chaker, Stefan Groeneweg, et al.
The Lancet. Diabetes & Endocrinology|December 3, 2016
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation studyAmand F Schmidt, Daniel I Swerdlow, Michael V Holmes, et al.
Lancet (London, England)|September 29, 2014
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trialsDaniel I Swerdlow, David Preiss, Karoline B Kuchenbaecker, et al.
Science Translational Medicine|June 3, 2016
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart diseaseRobert A Scott, Daniel F Freitag, Li Li, et al.
Nature Genetics|September 8, 2015
A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery diseaseMajid Nikpay, Anuj Goel, Hong-Hee Won, et al.
Pageof 51